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Extension of Grizzle’s Classic Crossover Design
James F. Reed III
Christiana Care Hospital System,
Newark, Delaware
The crossover design compares treatments A and B over two periods using sequences AB and BA (the
AB|BA design) and is the classic design most often illustrated and critiqued in textbooks. Other crossover
designs have been used but their use is relatively rare and not always well understood. This article
introduces alternatives to a randomized two-treatment, two-period crossover study design. One strategy,
which is to extend the classic AB|BA by adding a third period to repeat one of the two treatments, has
several attractive advantages; an added treatment period may not imply a large additional cost but will
allow carryover effects to be estimated and compared with the within-subject variability. Careful choice
of treatment sequences will enable the first two trial periods to constitute a conventional two-period
crossover trial if the third treatment period leads to excessive subject drop-outs. Four alternative designs
that address the first-order carryover effect are presented. These designs have more statistical power than
the classic design and allow the treatment effects to be estimated, even in the presence of a carryover
effect.
Key words: Crossover design, Grizzle, carryover effect.
have nearly doomed the crossover trial in
clinical research (Freeman, 1989; Senn, 1994;
Senn, 1996).
The most damning characteristic of a
crossover study is the potential of a carryover
effect of one treatment to the next period. To
address this issue, researchers typically include
washout periods in their study designs. These
washout periods are thought to be of sufficient
length to negate any lingering effect of one
treatment into the next period. Unfortunately,
what a sufficiently long washout period might be
remains unclear. In this article, and in most of
the literature on crossover designs, the
persistence of a carryover effect is assumed to
last for only a single period (a first-order
carryover effect) and it is also assumed that the
carryover effect is different for different
treatments. If a carryover effect is suspected in
any crossover trial, then a term for this effect
must be included in the model and accounted for
in the subsequent analysis. This article
introduces three simple alternatives to Grizzle’s
classic AB|BA crossover design. These designs
have more statistical power than the AB|BA
design and allow unbiased treatment effects to

Introduction
A crossover study is a longitudinal study in
which subjects receive a sequence of different
treatments; these designs are common in many
scientific disciplines. In AB|BA crossover
studies, subjects are randomly assigned to
receive either treatment A in the first treatment
period followed by treatment B in the second
period or treatment B in the first period followed
by treatment A in the second period. The
crossover study allows for a within-subject
comparison between treatments because each
subject serves as his or her own control, the
inter-patient variability is removed from the
comparison between treatments and it can
provide unbiased estimates for the differences
between
treatments.
However,
frequent
misapplications of the design in clinical trials
and even more frequent misanalysis of the data
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be estimated, even when
carryover effect is specified.

a

y21, has the expected value of E[c1] = E[y11 – y21]
= (π1 - π2) + (τA - τB) - λA, while in sequence
BA, the contrast c2, y21 – y22, has the expected
value of E[c2] = E [y21 – y22] = (π1 - π2) - (τA τB) - λB.
The difference between contrasts c1 and
c2 may be expressed is 2(τA - τB) - (λA - λB). It is
then possible to generate a hypothesis by
forming the differences in the two contrasts
between responses for the two periods. That
difference for the respective patients may be
expressed by HCROS:{2(τA - τB) - (λA - λB) = 0}.
HCROS is a combined null hypothesis tested by
the difference (or crossover) test of equality of
both the treatment effects and carryover effects
of A and B {τA = τB, λA = λB}. The treatment
effect and carryover effect are said to be aliased.
The rejection of HCROS is interpreted as
demonstrating that the direct and/or carryover
effects of A and B are different in the sense of a
prevailing larger response for one treatment than
the other across the two periods.
In sequence AB, the contrast c3 ,y11 +
y21, has the expected value of E[c3]= E[y11 + y21]
= 2μ + (π1 + π2 ) + (τA + τB) + λA, and in
sequence BA, the contrast c4 , y21 + y22, has the
expected value of E[c4] = E[y21 + y22] = 2μ + (π1
+ π2 ) + (τA + τB) + λB. The difference between
c3 and c4 differ by λA - λB, and is a measure of
the net carryover effect.
The hypothesis, HSEQ: λA = λB, has been
proposed for use when deciding whether the
rejection of the hypothesis HCROS is due mainly
to differences between the direct treatment
effects τA = τB or between the carryover effects
λA = λB. A non-significant HSEQ supports the
contention that there is a difference between τA
and τB as the primary contradiction of HCROS.
Alternatively, a significant HSEQ is interpreted as
indicating that the differences between λA and
λB may account for the contradiction of HCROS.
When assessing the SEQ hypothesis, the type II
error (falsely failing to reject the null hypothesis
of no first-order carryover effect) is of some
concern.
To reduce the probability of making a
type II error, the recommendation has been to
use larger than the usual α, such as 25%. In
bioequivalence studies, the commonly used
significance level in a bioequivalence study for

simple-order

The Traditional Crossover Model with
Continuous Data
The traditional design model assumes
that each treatment has a simple first-order
carryover effect that does not interact with the
direct effect of the treatment in the subsequent
period and that subject effects are either fixed or
random. Although a variety of models are
considered in the literature, virtually all of the
work in crossover designs has the following
traditional statistical model which assumes the
following for the response of patient yij.
If yijk denotes the observed response of
subject j (j = 1, …, n) in period i (i = 1, …, p),
then
yij = µ + πi + τd(i,j) + λd(i-1,j) + βj + εij.
where πi is the effect of period i; τd(i,j) is the
direct effect of treatment D, λd(i-1,j) is the simple
first-order carryover effect of treatment D and
d(i,j) is the treatment allocated to patient j in
period i, λd(0,j) = 0 for all j. It is assumed that all
these effects are fixed effects. βj is the effect of
patient j and εij is the error term. The random
subject effect, βj, and the experimental error, εij,
are assumed to be mutually independently
distributed as N (0, σ2β) and N(0, σ2ε).
The Classic AB|BA
The crossover design that compares
treatments A and B over two periods using
sequences AB and BA (the AB|BA design) is
the classic design and is most often illustrated
and critiqued in textbooks (Grizzle, 1965). Other
crossover designs have been utilized but their
use is relatively rare and is not always well
understood. For example, when more than two
treatments are to be compared, an extensive use
of each subject may be desirable when the
number of periods can be extended.
The primary purpose of an AB|BA
crossover trail is to estimate the treatment
contrast τA- τB (see Table 1). The period effects
π1 and π2, the first-order carryover effects λA and
λB, and µ are typically regarded as nuisance
parameters that should be eliminated from any
estimate. In sequence AB, the contrast c1, y11 –
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Table 1: Design AB|BA
AB|BA Design

Period 1
(k = 1)

Period 2
(k = 2)

Sequence AB (i = 1)

μ + π1 + τA

µ + π2 + τB + λA

Sequence BA (i = 2)

µ + π1 + τB

µ + π2 + τA + λB

Table 1 Notes:
Sequence AB (i = 1): E(yAB,1) = μAB,1 = μ + π1 + τA, E(yAB,2) = μAB,2 = μ + π2 + τB + λA
Sequence BA (i = 2): E(yBA,1) = μBA,1 = μ + π1 + τB, E(yAB,2) = μBA,2 = μ + π2 + τA + λB
In sequence AB, the contrast c1 has the expected value of E[c1]=E[y11 – y21]=(π1 - π2) + (τA - τB) - λA
In sequence BA, the contrast c2 has the expected value of E[c2]=E[y21 – y22]=(π1 - π2) - (τA - τB) - λB
In sequence AB, the contrast c3 has the expected value of E[c3]=E[y11 + y21] =
2μ+(π1+π2)+(τA+τB)+λA
In sequence BA, the contrast c4 has the expected value of E[c4]=E[y21 + y22] =
2μ+(π1+π2)+(τA+τB)+λB

universally optimal for estimating treatment
effects regardless of whether baseline
observations are available, and it is far more
efficient than the classic AB|BA (Laska,
Meisner & Kushner, 1983). However, in the
absence of any carryover effect, this design is
inefficient because many of the subjects will
contribute little - if any - information to the
estimate of treatment differences in the AA and
BB sequences.
The schematic for this design is shown
in Table 2. In sequence AB, the contrast, c1 =
(y11 - y12), has an expected value of E[c1] = E[y11
– y12] = (π1 - π2) + (τA - τB) - λA, in sequence
BA, the contrast c2 = (y21 - y22), has expected
value of E[c2] = E[y21 – y22] = (π1 - π2) - (τA - τB)
- λB, in sequence AA, the contrast c3 has an
expected value of E[c3] = E[y31 – y32] = (π1 - π2)
- λA, and in sequence BB, the contrast c4 has an
expected value of E[c4] = E[y41 – y42] = (π1 - π2)
- λB. A linear combination of c1 - c2 - c3 + c4
yields an unbiased estimate of the treatment
differences.
To derive an unbiased estimate of
carryover effects, c5 is defined in sequence AB
as y11 + y21. The expected value of c5 is then
E[c5] = E[y11 + y21] = 2µ + (π1 + π2) + (τA + τB)
+ λA. In sequence BA, c6 is defined as y21 + y22

SEQ is 25% (Chen & Tsong, 2007). This
recommendation may be followed for any
analyses.
A third hypothesis compares the two
sequences with respect to the responses for the
first period only. The prevailing strategy is to
use this test if a significant carryover effect is
identified. This test procedure is referred to as
PAR. When data from the second period are
ignored, an AB/BA crossover design has the
same structure as a PARallel group trial. PAR
addresses the hypothesis of equality of direct
treatment effects of A and B in the presence of
unequal carryover effects (Freeman, 1986;
Willan & Pater, 1986). An unbiased estimator of
the treatment effect can be found by means of a
t-test applied to the measurements obtained in
the first period only; however, unfortunately,
when using data from the first period only,
advantages of the crossover design are negated.
Balaam’s Design
To solve the first-order crossover
problem inherent in the traditional AB|BA
design, an extension of the Grizzle design is
needed. One alternative involves the use of
additional treatment sequences in the two
periods. For example, AA|AB|BA|BB (Balaam,
1968) could be utilized. This design is
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Table 2: Balaam’s Design (AB|BA|AA|BB)
AB|BA Design

Period 1
(k = 1)

Period 2
(k = 2)

Sequence AB (i = 1)

μ + π1 + τA

µ + π2 + τB + λA

Sequence BA (i = 2)

µ + π1 + τB

µ + π2 + τA + λB

Sequence AA (i = 3)

μ + π1 + τA

µ + π2 + τA + λA

Sequence BB (i = 4)

μ + π1 + τB

µ + π2 + τB + λB

Table 2 Notes:
Sequence AB (i = 1): E(yAB,1) = μAB,1 = μ + π1 + τA, E(yAB,2) = μAB,2 = μ + π2 + τB + λA
Sequence BA (i = 2): E(yBA,1) = μBA,1 = μ + π1 + τB, E(yAB,2) = μBA,2 = μ + π2 + τA + λB
Sequence AA (i = 3): E(yBA,1) = μAA,1 = μ + π1 + τA, E(yAB,2) = μBA,2 = μ + π2 + τA + λA
Sequence BB (i = 4): E (yBA,1) = μBA,1 = μ + π1 + τB, E (yAB,2) = μBA,2 = μ + π2 + τB + λB
In sequence AB, the contrast c1 has the expected value of E[c1] = E[y11 – y21]=(π1 - π2) + (τA - τB) - λA
In sequence BA, the contrast c2 has the expected value of E[c2] = E[y21 – y22]=(π1 - π2) - (τA - τB) - λB
In sequence AA, the contrast c3 has the expected value of E[c3] = E[y31 – y32]=(π1 - π2) - λA
In sequence BB, the contrast c4 has the expected value of E[c4] = E[y41 – y42]=(π1 - π2) - λB
In sequence AB, the contrast c5 has the expected value of E[c5] = E[y11 + y21]=2µ+(π1 + π2)+(τA + τB)+λA
In sequence BA, the contrast c6 has the expected value of E[c6] = E[y21 + y22]=2µ+(π1 + π2)+(τA + τB)+λB

periods. Two of these sequences, AAB and BBA
can be omitted because they do not enable
carryover effects from A and B to be examined
in the same subject and the first two periods do
not constitute a conventional two-period
crossover design.
The four remaining sequences ABB,
BAA, ABA and BAB may be used in pairs to
form two-treatment sequence three-period
designs, three-treatment sequence three-period
designs and one four-treatment sequence threeperiod design. Of the two-treatment sequence,
three-period, the ABB|BAA is known to be the
universally optimal design within the class of
three periods (Cheng & Wu, 1980; Laska &
Meisner, 1985; Hedayat & Stufken, 2003). In
these designs half the subjects are randomly
assigned to each sequence.
Two additional efficient two-treatment,
three-period designs are the AAB|ABA and
ABA|ABB designs. Another efficient twotreatment, three-period design is the ABB|
BAA|ABA|BAB (Ebbutt, 1984). This set of
designs with equal number of subjects per
sequence is able to estimate all parameters in the

and has the expected value of E[c6] = E[y21 +
y22] = 2µ + (π1 + π2) + (τA + τB) + λB. A linear
combination of [½(c5 - c6 - c3 + c4)] yields an
unbiased estimate of carryover effects (λA - λB).
Two-Treatment, Three-Period Crossover Design
The second design strategy is to extend
the AB|BA design by adding a third period and
repeating one of the two treatments: This has
several attractive advantages. For example, in
clinical studies major costs are associated with
planning and patient recruitment rather than
routine follow-up, thus, an added period may not
imply a large additional cost. The added
treatment period will allow carryover effects to
be estimated and compared with the withinsubject variability. Finally, a careful selection of
the treatment sequences to be used will insure
that the first two trial periods constitute a
conventional two-period crossover trial if the
third treatment period leads to excessive subject
drop-outs.
In three period crossover trial with two
treatments, six possible treatment sequences can
result when two treatments are applied in three
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between c3 and c4 forms an unbiased estimate of
λA - λB.
A second model for a two-treatment
three-period crossover trial, ABA| BAB, is
shown in Table 4. In sequence ABA, the
expected value of E [c1] = E [½ (2y11 - y21 - y31)]
= ½{(2π1 - π2 - π3) + (τA - τB) - λA - λB}. In
sequence BAB, the expected value of E [c2] = E
[½ (2y12 - y22 - y32)] = ½{(2π1 - π2 - π3) - (τA τB) - λA - λB}. The difference between the means
of the two contrasts c1 and c2 forms an unbiased
estimator of τA - τB. In testing for carryover
effect, let c3 = y11 + 2y21 + y31 in sequence ABA
and the expected value of E [c3] = E [(y11 + 2y21
+ y31)] = {4µ + (π1 + 2π2 + π3) + 2(τA + τB) +
2λA + λB}. In sequence BAB, define c4 = y21 +
2y22 + y23 with the expected value of E [c4] = E
[(y21 + y22 - 2y23)] = {4µ + (π1 + 2π2 + π3) + 2(τA
+ τB) + 2λB + λA}. The difference between c3
and c4 then forms an unbiased estimate of λA λB.

traditional model and provide a good estimate of
the treatment contrast (Ebbutt, 1984; Heydat &
Stufken, 2003, Liang & Carriere, 2010).
A balanced model for the two-treatment
three-period crossover trial, ABB| BAA, is
shown in Table 3. In sequence ABB, the
contrast, c1 = (2y11 - y21 - y31), has the
expectation ¼{(2π1 - π2 - π3) + 2(τA - τB) - λA λB}. In sequence BAA, the contrast c2 = (2y21 y22 – y32) has the expectation ¼{(2π1 - π2 - π3) +
2(τB - τA) - λA - λB}. The difference between
contrast c1 and c2 forms an unbiased estimator of
τA - τB. It appears that the central problem of the
AB|BA has been solved by simply extending the
design by one period. An unbiased estimator of
any carryover effect, λA - λB may also be
constructed. Consider c3 = (y11 - 2y21 + y31) and
c4 = (y21 - 2y22 + y23). The expected value of E
[c3] is ⅓ {(π1 - 2π2 + π3) + (τA - τB) - 2λA + λB}
and the expected value of E [c4] is ⅓ {(π1 - 2π2 +
π3) + (τB - τA) - 2λB + λA}. The difference

Table 3: ABB|BAA Design
Sequence

Period 1
(k = 1)

Period 2
(k = 2)

Period 3
(k = 3)

ABB (i = 1)

µ + π1 + τA

µ + π2 + τB + λA

µ + π3 + τB + λB

BAA (i = 2)

µ + π1 + τB

µ + π2 + τA + λB

µ + π3 + τA + λA

Table 3 Notes:
ABB (i = 1): E(yABB,1) = μ + π1 + τA, E(yABB,2) = μ + π2 + τB + λA, E(yABB,3) = μ + π3 + τB + λB
BAA (i = 2): E(yBAA,1) = μ + π1 + τB, E(yBAA,2) = μ + π2 + τA + λB, E(yBAA,3) = μ + π3 + τA + λA
In sequence ABB, the expected value of E[c1]=E[¼(2y11 - y21 - y31)]=¼{(2π1 - π2 - π3)+2(τA - τB) - λA λB}
In sequence BAA, the expected value of E[c2]=E[¼ (2y21 - y22 - y32)]=¼{(2π1 - π2 - π3) + 2(τB - τA) - λA
- λB}
In sequence ABB, the expected value of E[c3]=E[⅓ (y11 - 2y21 + y31)]=⅓{(π1 - 2π2 + π3) + (τA - τB) - 2λA
+ λB}
In sequence BAA, the expected value of E[c4]=E[⅓ (y21 - 2y22 + y23)]=⅓{(π1 - 2π2 + π3) + (τB - τA) - 2λB
+ λA}
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Table 4: ABA|BAB
Sequence

Period 1
(k = 1)

Period 2
(k = 2)

Period 3
(k = 3)

ABA (i = 1)

µ + π1 + τA

µ + π2 + τB + λA

µ + π3 + τA + λB

BAB (i = 2)

µ + π1 + τB

µ + π2 + τA + λB

µ + π3 + τB + λA

Table 4 Notes:
ABA (i = 1): E(yABB,1) = μ + π1 + τA, E(yABA,2) = μ + π2 + τB + λA, E(yABA,3) = μ + π3 + τA + λB
BAB (i = 2): E(yBAB,1) = μ + π1 + τB, E(yBAB,2) = μ + π2 + π3 + λB, E(yBAB,3) = μ + π3 + τB + λA
In sequence ABA, E[c1] = E[½ (2y11 - y21 - y31)] = ½{(2π1 - π2 - π3) + (τA - τB) - λA - λB }
In sequence BAB, E[c2] = E[½ (2y21 - y22 - y32)] = ½{(2π1 - π2 - π3) - (τA - τB) - λA - λB}
In sequence ABA, E[c3] = E[(y11 + 2y21 + y31)] = {4µ + (π1 + 2π2 + π3) + 2(τA + τB) + 2λA + λB}
In sequence BAB, E[c4] = E[(y21 + 2y22 + y32)] = {4µ + (π1 + 2π2 + π3) + 2(τA + τB) + 2λB + λA}

between the observed periods and may help in
overcoming the carryover effect if the carryover
effect is not expected to persist, however,
inserting rest periods may not be feasible. The
insertion of a rest period between each pair of
successive periods increases the total duration of
the experiment and there is no guarantee that the
wash out period is sufficiently long enough to
eliminate any carryover effect. An alternative is
to design the experiment in such a manner that
the difference in treatment effects may be
estimated after adjusting for the presence of
possible carryover effects.
Despite some of the problems associated
with the use of a crossover design its advantages
are attractive. Although crossover designs have
been in use for several decades, issues relating to
the finding optimal crossover designs have been
addressed only in about the last 30 years. There
has been a continuous effort in the general area
of optimal crossover designs, often assuming
different underlying models. The uniform
consistency has been the inclusion of carryover
effect. These models, in turn, may be regarded
as an approximation to the real world
relationship between the response and the effects
included in the model. A caution worth noting:
Any crossover design under an assumed model
might not be the optimal if the model is
incorrectly specified.

Discussion
Advantages of a crossover trial are that each
subject is used as their own control, optimal two
treatment three-period crossover designs are
statistically efficient and these designs require
fewer subjects for the same number of
observations than do non-crossover designs.
This latter advantage is an important aspect,
particularly in situations where the experimental
subjects are scarce and are expensive to recruit
and maintain in the study. Another advantage of
crossover designs is that, by a defining a specific
choice of treatment sequences, it is possible to
estimate important treatment contrasts even
when assuming a carryover effect in the overall
model.
The major concern in a crossover design
is the presence of carryover effects. In any given
period, an observation from a subject is affected
not only by the direct effect of a treatment in the
period in which it is applied, but possibly by the
effect of a treatment applied in the preceding
period. In a clinical study, particularly a drug
study, one way to avoid the impact of a
carryover effect is to insert a rest period between
two successive periods with the hope that the
carryover effect would wash out during this
period. This is the most common method of
handling effects of drug studies. The insertion of
rest periods effectively increases the interval
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Conclusion
Although there are crossover models that specify
higher order carryover effects, the two-treatment
three-period designs described herein maintain
their optimality characteristics. To address the
potential of first-order carryover effect, the
classic AB|BA crossover design could be
extended to a three-period design using one of
the designs outlined. In effect, the added
treatment period permits any carryover effects to
be estimated and compared with the withinsubject variability. A careful selection of the
treatment sequences would reduce to a classic
two-treatment,
two-period
conventional
crossover trial if the third treatment period leads
to excessive subject drop-outs.
The statistical properties of twotreatment, three-period designs is well known
but seldom used. When the traditional statistical
model is acknowledged as being reasonable,
these designs provide a framework to estimate
treatment effects even in the presence of a
carryover effect and effectively provide a way to
address the impasse imposed by the classic
AB|BA design.
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